Initially developed as glucose-lowering agents, SGLT2 inhibitors have demonstrated significant cardioprotective effects across diverse clinical settings and patient populations, including those without diabetes [23,24,25,26,27]. The gene discussed is SLC5A2; the disease is diabetes mellitus.